CRISPR Therapeutics, a leading gene editing company, has announced a registered direct offering of 3,916,082 common shares. The shares are offered at an issue price of $71.50 each, with the Nasdaq Global Market listing under the symbol 'CRSP.' The offering is expected to close on or about February 27, 2024, with T+9 settlement. CRISPR Therapeutics intends to use the net proceeds for general corporate purposes, including research and clinical development, manufacturing infrastructure, and working capital. The offering is made pursuant to a prospectus supplement filed with the SEC and is subject to customary closing conditions.

CRISPR Therapeutics, a leading gene editing company, has announced a registered direct offering of 3,916,082 common shares. The shares are offered at an issue price of $71.50 each, with the Nasdaq Global Market listing under the symbol 'CRSP.' The offering is expected to close on or about February 27, 2024, with T+9 settlement. CRISPR Therapeutics intends to use the net proceeds for general corporate purposes, including research and clinical development, manufacturing infrastructure, and working capital. The offering is made pursuant to a prospectus supplement filed with the SEC and is subject to customary closing conditions.